eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025
eXoZymes (NASDAQ: EXOZ), a company specializing in AI-engineered enzymes for converting sustainable feedstock into chemicals, medicines, and biofuels, has announced its upcoming fourth quarter and full year 2024 financial results conference call. The webinar is scheduled for Wednesday, April 2, 2025, at 4:30 p.m. Eastern Time.
CEO Michael Heltzen will lead the presentation alongside management team members to discuss quarterly results, recent developments, ongoing initiatives, and future milestones. A press release containing detailed financial results will be published before the call. Investors can access the webinar through pre-registration or the company's investor relations website.
eXoZymes (NASDAQ: EXOZ), un'azienda specializzata in enzimi progettati con intelligenza artificiale per convertire materie prime sostenibili in prodotti chimici, medicinali e biocarburanti, ha annunciato la sua prossima conferenza telefonica sui risultati finanziari del quarto trimestre e dell'intero anno 2024. Il webinar è programmato per mercoledì 2 aprile 2025, alle 16:30 ora orientale.
Il CEO Michael Heltzen guiderà la presentazione insieme ai membri del team di gestione per discutere i risultati trimestrali, gli sviluppi recenti, le iniziative in corso e i traguardi futuri. Un comunicato stampa contenente risultati finanziari dettagliati sarà pubblicato prima della chiamata. Gli investitori possono accedere al webinar tramite registrazione preventiva o attraverso il sito web delle relazioni con gli investitori dell'azienda.
eXoZymes (NASDAQ: EXOZ), una empresa especializada en enzimas diseñadas con inteligencia artificial para convertir materias primas sostenibles en productos químicos, medicamentos y biocombustibles, ha anunciado su próxima conferencia telefónica sobre los resultados financieros del cuarto trimestre y del año completo 2024. El seminario web está programado para miércoles 2 de abril de 2025, a las 4:30 p.m. hora del Este.
El CEO Michael Heltzen liderará la presentación junto a los miembros del equipo de gestión para discutir los resultados trimestrales, los desarrollos recientes, las iniciativas en curso y los hitos futuros. Se publicará un comunicado de prensa con resultados financieros detallados antes de la llamada. Los inversores pueden acceder al seminario web a través de una preinscripción o en el sitio web de relaciones con inversores de la empresa.
eXoZymes (NASDAQ: EXOZ), 지속 가능한 원료를 화학 물질, 의약품 및 바이오 연료로 전환하기 위해 AI 엔지니어링 효소를 전문으로 하는 회사가 2024년 4분기 및 전체 연도 재무 결과에 대한 컨퍼런스 콜을 발표했습니다. 웨비나는 2025년 4월 2일 수요일 오후 4시 30분 동부 표준시에 예정되어 있습니다.
CEO 마이클 헬첸이 발표를 이끌며 관리팀과 함께 분기별 결과, 최근 개발 사항, 진행 중인 이니셔티브 및 향후 이정표에 대해 논의할 것입니다. 통화 전에 자세한 재무 결과를 포함한 보도자료가 게시될 예정입니다. 투자자는 사전 등록 또는 회사의 투자자 관계 웹사이트를 통해 웨비나에 액세스할 수 있습니다.
eXoZymes (NASDAQ: EXOZ), une entreprise spécialisée dans les enzymes conçues par intelligence artificielle pour convertir des matières premières durables en produits chimiques, médicaments et biocarburants, a annoncé sa prochaine conférence téléphonique sur les résultats financiers du quatrième trimestre et de l'année 2024. Le webinaire est prévu pour mercredi 2 avril 2025, à 16h30, heure de l'Est.
Le PDG Michael Heltzen dirigera la présentation avec des membres de l'équipe de direction pour discuter des résultats trimestriels, des développements récents, des initiatives en cours et des jalons futurs. Un communiqué de presse contenant des résultats financiers détaillés sera publié avant l'appel. Les investisseurs peuvent accéder au webinaire par préinscription ou via le site web des relations investisseurs de l'entreprise.
eXoZymes (NASDAQ: EXOZ), ein Unternehmen, das sich auf KI-entwickelte Enzyme zur Umwandlung nachhaltiger Rohstoffe in Chemikalien, Medikamente und Biokraftstoffe spezialisiert hat, hat seine bevorstehende Telefonkonferenz zu den finanziellen Ergebnissen des vierten Quartals und des gesamten Jahres 2024 angekündigt. Das Webinar ist für Mittwoch, den 2. April 2025, um 16:30 Uhr Eastern Time angesetzt.
CEO Michael Heltzen wird die Präsentation zusammen mit Mitgliedern des Managementteams leiten, um die Quartalsergebnisse, aktuelle Entwicklungen, laufende Initiativen und zukünftige Meilensteine zu besprechen. Eine Pressemitteilung mit detaillierten finanziellen Ergebnissen wird vor dem Anruf veröffentlicht. Investoren können über eine Voranmeldung oder die Investor-Relations-Website des Unternehmens auf das Webinar zugreifen.
- None.
- None.
Monrovia, CA , March 26, 2025 (GLOBE NEWSWIRE) -- eXoZymes Inc. (NASDAQ: EXOZ) [“eXoZymes”] - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - plans to host a webinar on Wednesday, April 2, 2025 at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter and full year 2024. A press release detailing these results will be issued prior to the call.
Michael Heltzen, CEO of eXoZymes will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer period.
Investors can pre-register now for the webinar HERE. The live webinar can also be accessed on the day of the event through eXoZymes' investor relations website at https://exozymes.com/investor#webinar
About eXoZymes
Founded in 2019, the company has developed a platform that - as a historic first - offers the tools and insight to control and optimize nature’s own processes to produce chemical compounds, enabling the company’s partners to replace traditional chemical production methods with a new sustainable, scalable, and eco-friendly alternative: Exozymes.
Exozymes are advanced enzymes enhanced with AI and bioengineering to thrive in a bioreactor outside of living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform biomass into essential chemicals, medicines, and biofuels.
By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the logical successor to most SynBio projects. After SynBio, this pioneering technology enables entering the exozymes era of biotechnology.
While the company, eXoZymes Inc., has introduced “exozymes” (エキソザイム in Japanese katakana) as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption.
Learn more on exozymes.com
eXoZymes Safe Harbor
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of eXoZymes’ quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.
Investor relations contact
Email: ir@exozymes.com
eXoZymes media contact
Lasse Görlitz, VP of Communications
(858) 319-7135
press@exozymes.com
FAQ
When will eXoZymes (EXOZ) release its Q4 and full year 2024 earnings?
What time is eXoZymes (EXOZ) Q4 2024 earnings call?
How can investors join eXoZymes (EXOZ) Q4 2024 earnings call?
Who will present at eXoZymes (EXOZ) Q4 2024 earnings call?
